Target family: 1H. Liver X receptor-like receptors (type: nhr)
Target: Liver X receptor-&beta;

Ligand: 22R-hydroxycholesterol (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5.52 pEC50
Reference (Journal): An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha.
Published in: Nature

Ligand: 24(S), 25-epoxycholesterol (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis.
Published in: Nat Chem Biol

Ligand: 24(S), 25-epoxycholesterol (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway.
Published in: J Biol Chem

Ligand: 24(S)-hydroxycholesterol (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5.5 pEC50
Reference (Journal): Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway.
Published in: J Biol Chem

Ligand: 27-hydroxycholesterol (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.15 pEC50
Reference (Journal): 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells.
Published in: J Biol Chem

Ligand: acetyl-podocarpic dimer (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9 pEC50
Reference (Journal): A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux.
Published in: J Biol Chem

Ligand: AZ12260493 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 7.960000038146973 pKi
Reference (Webpage): AZD9291.

Ligand: compound 17l [PMID: 26288691] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.739999771118164 pIC50
Reference (Journal): Styrylphenylphthalimides as Novel Transrepression-Selective Liver X Receptor (LXR) Modulators.
Published in: ACS Med Chem Lett

Ligand: desmosterol (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.849999904632568 pKi
Reference (Journal): Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands.
Published in: J Biol Chem

Ligand: GSK2033 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.5 pIC50
Reference (Journal): Discovery of tertiary sulfonamides as potent liver X receptor antagonists.
Published in: J Med Chem

Ligand: GSK9772 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Primary target: no
Median affinity: 7.519999980926514 pIC50
Reference (Journal): Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity.
Published in: J Med Chem

Ligand: GW3965 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.52 pEC50
Reference (Journal): Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines.
Published in: J Med Chem

Ligand: IMB-808 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 6.28000020980835 pEC50
Reference (Journal): Identification of a Novel Liver X Receptor Agonist that Regulates the Expression of Key Cholesterol Homeostasis Genes with Distinct Pharmacological Characteristics.
Published in: Mol Pharmacol

Ligand: L-783483 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.2 pKd
Reference (Journal): A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a).
Published in: Endocrinology

Ligand: rovazolac (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6 pEC50
Reference (Patent): Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions

Ligand: SR9238 (Synthetic organic)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: no
Primary target: no
Median affinity: 7.369999885559082 pIC50
Reference (Journal): A liver-selective LXR inverse agonist that suppresses hepatic steatosis.
Published in: ACS Chem Biol

Ligand: T0901317 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.3 pEC50
Reference (Journal): Role of LXRs in control of lipogenesis.
Published in: Genes Dev